The treatment of acute myeloid leukemia type M2 includes general treatment and anti-leukemia treatment.
1. General treatment
(1) Prevention and treatment of infection: AML patients are often accompanied by granulocytopenia or lack of granulocytes, especially after chemotherapy and radiotherapy, at this time, patients should stay in laminar flow ward or sterilized isolation ward.
(2) Component transfusion support: red blood cell concentrate can be transfused for severe anemia, and platelet suspension can be transfused when platelet count is too low.
(3) Nutritional maintenance: leukemia is a serious consumptive disease, patients should pay attention to nutritional supplementation, and should be given high-protein, high-calorie, easy-to-digest food.
2. Anti-leukemia treatment
(1) Induction of remission therapy: the most commonly used are IA regimen (desmethoxylated erythromycin + cytarabine) and DA regimen (erythromycin + cytarabine), and HA regimen (hypertriglyceride + cytarabine) can also be used.
(2) Post-remission treatment
① Poor prognosis group: if accompanied by isolated NPM1 mutation, allo-HSCT, i.e. allogeneic hematopoietic stem cell transplantation, is preferred.
② Good prognosis group: if monosomy, prefer high-dose cytarabine-based chemotherapy, followed by allo-HSCT after relapse.
(iii) Intermediate prognosis group: if inversion of chromosome 16 occurs, both allo-HSCT with mismatch and high-dose cytarabine-based chemotherapy can be used.
Patients with acute myeloid leukemia type M2 should go to the hospital as soon as possible, and should not use drugs on their own.